Matchpoint Therapeutics launches with $100 million to deliver on the promise of precision covalent medicines for immune diseases
Acing the future
of covalent medicines.
Matchpoint is discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
The power of covalency
The irreversible bond formed between a covalent medicine and its protein target imparts unique pharmacological benefits and greatly expands the number of disease-causing proteins that can be therapeutically targeted.
Deployment of covalent molecules during chemoproteomics screening enables detection of allosteric, transient, and cryptic binding pockets that would otherwise be missed with traditional, high throughput screening methods.
The durable target engagement achieved by covalent molecules results in significantly improved potency over non-covalent approaches. This feature enables targeting proteins which are otherwise unamenable to small molecule intervention, including those with high affinity for natural ligands and those requiring near-complete modulation.
Covalent molecules form a bond to a protein through a single, reactive amino acid. When that amino acid is only present in the disease-causing protein, it allows precise targeting over other closely related proteins, including members of the same family and mutant over wild-type forms.
The prolonged duration of action of covalent molecules dissociates pharmacokinetics (PK) from pharmacodynamics (PD), an effect known as PK-PD decoupling. This property translates to sustained efficacy after metabolic clearance and achievement of therapeutic indices otherwise unattainable.
Matchpoint leverages a novel labeling technology to probe deeper into the proteome than historically possible to identify new binding sites on disease-causing proteins and to scan for proteome-wide selectivity of drug candidates across all stages of drug discovery. We deploy our high throughput cellular screening methods to prospect for selective binders in two complementary ways:
Matchpoint utilizes machine learning to extract insights from extensive data sets — our proprietary chemoproteomics screens, publicly available data, and state-of-the-art predictors of protein conformation and protein-protein interaction — and design algorithms that:
Evolving covalent library
Matchpoint is building a proprietary library of covalent compounds that range from fragments, which maximize the probability of identifying hits against cryptic pockets, to lead-like and drug-like compounds that require far less time and fewer resources to advance to the clinic.
Our library is continuously expanded and refined using insights from our predictive algorithms and growing understanding of the rules of covalency.
Who we are
Our core values serve as the foundation for everything we do.
Matchpoint brings together passionate drug hunters, deep technical experts, and seasoned company builders unified by the goal of developing precision covalent medicines that transform the lives of those impacted by serious disease.
We love what we do, we are bold, we create energy.
We are authentic, we do the right thing, we learn from successes and failures.
We build lasting bonds, we get involved, we take responsibility.
We make a difference, we combine our strengths, we create a legacy.
Are you a match?
We are looking for passionate individuals who are ready to make their mark as part of a collaborative team. Take a look at our openings to see if you’re a match!
Board of Directors
Mark Tebbe, PhD
Jared Cumming, PhD
Mark Jedrychowski, PhD
Suresh Singh, PhD
Wei Li, MD
Paul Renhowe, PhD
Bruce Booth, DPhil
Dan Becker, MD, PhD
Edward Chouchani, PhD
Jernej Godec, PhD
Christine Borowski, PhD
Luba Greenwood, JD
Jason Hafler, PhD
Chris Gagliardi, PhD
Christine Brennan, PhD
Nathanael Gray, PhD
Tinghu Zhang, PhD
Jianwei Che, PhD
Edward Chouchani, PhD
Matchpoint in the news